Recce Pharmaceuticals Ltd. Statistics
Want to see AU:RCE full AI Analyst Report?
Recce Pharmaceuticals Ltd. (RCE) Stock Statistics & Valuation Metrics
Total Valuation
Recce Pharmaceuticals Ltd. has a market cap or net worth of AUD 111.63M. The enterprise value is AUD 124.87M.
- Market Cap
- AUD 111.63M
- Enterprise Value
- AUD 124.87M
Share Statistics
Recce Pharmaceuticals Ltd. has 305,844,100 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 305,844,100
- Owned by Insiders
- 2.56%
- Owned by Institutions
- ―
Financial Efficiency
Recce Pharmaceuticals Ltd.’s return on equity (ROE) is 0.89 and return on invested capital (ROIC) is 238.75%.
- Return on Equity (ROE)
- 0.89
- Return on Assets (ROA)
- -1.75
- Return on Invested Capital (ROIC)
- 238.75%
- Return on Capital Employed (ROCE)
- 2.97
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.87M
- Employee Count
- 8
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Recce Pharmaceuticals Ltd. is -7.14. Recce Pharmaceuticals Ltd.’s PEG ratio is -0.39.
- PE Ratio
- -7.14
- PS Ratio
- 0.00
- PB Ratio
- -6.40
- Price to FCF
- -11.37
- Price to Operating Cash Flow
- -10.82
- PEG Ratio
- -0.39
Income Statement
In the last 12 months, Recce Pharmaceuticals Ltd. had revenue of 0 and earned -14.96M in profits. Earnings per share was -0.05.
- Revenue
- 0
- Gross Profit
- -356.40K
- Operating Income
- -23.16M
- Pretax Income
- -23.84M
- Net Income
- -14.96M
- EBITDA
- -22.81M
- Earnings Per Share (EPS)
- -0.05
Cash Flow
In the last 12 months, operating cash flow was -9.89M and capital expenditures -61,964, giving a free cash flow of -9.95M billion.
- Operating Cash Flow
- -9.89M
- Free Cash Flow
- -9.95M
- Free Cash Flow per Share
- -0.03
Dividends & Yields
Recce Pharmaceuticals Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -8.80%
- Earnings Yield
- -13.98%
Stock Price Statistics
- Beta
- 1.19
- 52-Week Price Change
- -16.85%
- 50-Day Moving Average
- 0.33
- 200-Day Moving Average
- 0.43
- Relative Strength Index (RSI)
- 61.50
- Average Volume (3m)
- 260.24K
Important Dates
Recce Pharmaceuticals Ltd. upcoming earnings date is Mar 01, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Aug 31, 2026
- Next Earnings Date
- Mar 01, 2027
- Ex-Dividend Date
- ―
Financial Position
Recce Pharmaceuticals Ltd. as a current ratio of 0.44, with Debt / Equity ratio of -62.44%
- Current Ratio
- 0.44
- Quick Ratio
- 0.44
- Debt to Market Cap
- 0.09
- Net Debt to EBITDA
- -0.34
- Interest Coverage Ratio
- -13.96
Taxes
In the past 12 months, Recce Pharmaceuticals Ltd. has paid -8.88M in taxes.
- Income Tax
- -8.88M
- Effective Tax Rate
- 0.37
Enterprise Valuation
Recce Pharmaceuticals Ltd. EV to EBITDA ratio is -5.41, with an EV/FCF ratio of -12.15.
- EV to Sales
- 0.00
- EV to EBITDA
- -5.41
- EV to Free Cash Flow
- -12.15
- EV to Operating Cash Flow
- -12.22
Balance Sheet
Recce Pharmaceuticals Ltd. has AUD 2.69M in cash and marketable securities with AUD 10.44M in debt, giving a net cash position of -AUD 7.75M billion.
- Cash & Marketable Securities
- AUD 2.69M
- Total Debt
- AUD 10.44M
- Net Cash
- -AUD 7.75M
- Net Cash Per Share
- -AUD 0.03
- Tangible Book Value Per Share
- -AUD 0.06
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Recce Pharmaceuticals Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 42.51%
Scores
- Smart Score
- 7
- AI Score
- 47

